US EditionData from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Rezpegaldesleukin showed statistically significant reductions in disease severity for atopic dermatitis and alopecia areata in Phase 2b trials, supporting planned Phase 3 development.
- On Friday, Nektar Therapeutics showcased Phase 2b data for rezpegaldesleukin at the American Academy of Dermatology Annual Meeting in Denver, presenting efficacy results in atopic dermatitis and alopecia areata.
- The 393-patient REZOLVE-AD study demonstrated consistent reduction in mean EASI scores over 16 weeks, with patients achieving comparable EASI-75 and EASI-90 response rates regardless of baseline disease severity.
- Dr. David Rosmarin, Chair of the Department of Dermatology at Indiana University School of Medicine, reported 36-week alopecia areata data showing a 28.2% mean SALT reduction with high-dose rezpegaldesleukin versus 11.2% with placebo.
- Stimulating regulatory T-cells helps rebalance the immune system, according to Dr. Raj Chovatiya, Associate Professor at Rosalind Franklin University of Medicine and Science, potentially providing consistent improvement across broader patient populations.
- Nektar plans to initiate the Phase 3 ZENITH-AD program in the second quarter of 2026 to evaluate rezpegaldesleukin in moderate-to-severe atopic dermatitis patients, building on Phase 2b efficacy results.
18 Articles
18 Articles
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting (2026-03-28)
Raj Chovatiya, Associate Professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research, in an oral poster session entitled " Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2 b Efficacy, Safety, and Baseline Severity–...
New data highlight benefits of rezpegaldesleukin for severe alopecia areata
DENVER — Rezpegaldesleukin improved the severity of hair loss among adults with severe and very severe alopecia areata, according to results from the phase 2b REZOLVE-AA study.“This is a proof-of-concept study demonstrating a targeted treatment that can help patients with severe alopecia areata,” David Rosmarin, MD, chair of the department of dermatology, associate professor of
Coverage Details
Bias Distribution
- 84% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
